【摘要】 2014年12月,欧洲骨质疏松和骨关节炎临床及经济学协会(ESCEO)发布了膝骨关节炎(OA)治疗规则。此篇论文提供了中国OA专家将治疗规则应用于中国临床所做的评估和认可,目的是就如何为膝关节OA患者制定治疗流程提出切实可行的建议。在治疗的第1步,建议采用对症的缓慢起效骨关节炎治疗药物(SYSADOA)作为药物维持疗法,关于SYSADOA只有处方药结晶型硫酸氨基葡萄糖(p CGS)和处方药硫酸软骨素提供了高质量的证据。同时可合并扑热息痛等非甾体抗炎药物(NSAIDs),但只能作为紧急镇痛药物。外用非甾体抗炎药(NSAIDs)也可对症治疗。口服NSAIDs在第2步持续症状的高级治疗中维持核心作用。但是,口服NSAIDs在胃肠道和心血管安全性方面存在较大差异性。关节内注射透明质酸可产生持续临床益处,接受一个治疗疗程后,效应可持续长达6个月。作为手术之前的最后一步,缓释型曲马多(一种较弱的阿片类物质)可产生持续镇痛作用,且耐受性较好。更多还原

【Abstract】 In December 2014, The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis(ESCEO) published a treatment algorithm for the management of knee osteoarthritis(OA). This current paper provides an assessment and endorsement of the algorithm by Chinese experts in OA for use in Chinese clinical practice, with the aim of providing easy-to-follow advice on how to establish a treatment flow in patients with knee OA. In step 1, background maintenance therapy with symptomatic slow-acting drugs for osteoarthritis(SYSADOA) is recommended, for which high-quality evidence is provided only for the formulations of patented crystalline glucosamine sulphate(p CGS)(Rottapharm now Meda) and prescription chondroitin sulphate. Paracetamol may be added for rescue analgesia only. Topical non-steroidal anti-inflammatory drugs(NSAIDs) may provide additional symptomatic treatment with the same degree of efficacy as oral NSAIDs without the systemic safety concerns. Oral NSAIDs maintain a central role in step 2 advanced management of persistent symptoms. However, oral NSAIDs are highly heterogeneous in terms of gastrointestinal and cardiovascular safety profile. Intra-articular hyaluronic acid as a next step provides sustained clinical benefit with effects lasting up to 6 months after a short-course of weekly injections. As a last step before surgery, the slow titration of sustained-release tramadol, a weak opioid, affords sustained analgesia with improved tolerability.更多还原